Oncolytics Biotech (TSE:ONC) Sets New 1-Year Low – Here’s What Happened

Shares of Oncolytics Biotech Inc. (TSE:ONC) hit a new 52-week low during trading on Tuesday . The stock traded as low as C$0.86 and last traded at C$0.87, with a volume of 254159 shares traded. The stock had previously closed at C$0.93.

Wall Street Analyst Weigh In

Separately, Raymond James raised Oncolytics Biotech to a “moderate buy” rating in a report on Thursday, November 14th.

Oncolytics Biotech Price Performance

The company has a debt-to-equity ratio of 11.75, a current ratio of 2.99 and a quick ratio of 8.86. The stock’s fifty day simple moving average is C$1.10 and its 200-day simple moving average is C$1.30. The stock has a market cap of C$70.14 million, a P/E ratio of -2.54 and a beta of 1.35.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.